Joel Greenblatt acquired 10.8 Thousand Alnylam Pharmaceuticals shares worth $1.57 Million. That's 0.03% of their equity portfolio (658th largest holding). The first Alnylam Pharmaceuticals trade was made in Q2 2017. Since then Joel Greenblatt bought shares eight more times and sold shares on five occasions. The investor's estimated purchase price is $1.84 Million, resulting in a loss of 15%.